Based on a strategy to deliver a broad range of assays for use on the Celerus Wave® System, Jason Lusk, Vice President of Sales and Marketing, today announced the availability of Wave Direct Immunofluorescence (IF).
“The Wave Direct IF assay provides clinical and research pathology labs with the ability to perform rapid, direct Immunofluorescence on the Wave System,” Lusk said. "Already novel for its ability to provide Rapid IHC®, additional assays, such as Direct IF, make the Celerus Wave System the most diverse staining platform available today."
Direct IF is used in a number of clinical applications in anatomic pathology laboratories. Among them, direct IF assays provide pathologists with adjunctive information to aid in the diagnosis of renal disease. “By standardizing this assay and reducing turnaround times, the Celerus Wave® System continues to deliver anatomic pathology labs with the flexibility required to meet their objective of improving patient care,” said Lusk.
Celerus Diagnostics introduced Rapid IHC® with its Wave System in 2008. In addition to standard immunohistochemisty applications, breast, neuro and Mohs surgeons also benefit significantly from intraoperative results made possible in just 15 minutes.
Understanding long COVID: A call for better diagnosis and treatment